CD8A and neoplasm: The number of CD4+, CD8+, CD25+, FoxP3+ and CD20+ TILs in the late phase of tumor development (pT3–pT4) was significantly lower compared to that observed for less advanced tumors (pT1–pT2) (Figure 1A–E).